NEW YORK, March 26, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Boston Scientific Corporation (NYSE: BSX), Horizon Pharma Inc. (NASDAQ: HZNP), Alkermes Plc (NASDAQ: ALKS), Agilent Technologies Inc. (NYSE: A), and Becton, Dickinson and Co. (NYSE: BDX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
BostonScientificCorporationAnalystNotes
On March 19, 2014, Boston Scientific Corporation (Boston Scientific) announced that in recognition for delivering world class results and demonstrating an ongoing commitment to leading and influencing a strong culture of operational excellence at its Maple Grove, Minnesota manufacturing facility, the Company was awarded a Shingo award from the Shingo Institute. The Shingo Institute is part of the Jon M. Huntsman School of Business at Utah State University. Commenting on the news, Dale Hentges, Vice President, Maple Grove Operations, remarked, "We are proud of our consistent and sustained efforts to drive quality, reduce cost and deliver innovative new products across our global operation. The Shingo Model is a world-class standard for operational excellence, and our team is honored to receive this recognition for our progress and efforts." The full analyst notes on Boston Scientific Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03262014/BSX/report.pdf
HorizonPharmaInc.AnalystNotes
On March 19, 2014, Horizon Pharma Inc. (Horizon Pharma) reported that it has entered into a definitive agreement with Vidara Therapeutics International Ltd. (Vidara). As per the agreement, Horizon Pharma will acquire Vidara through a reverse merger for stock and cash valued at approximately $660 million, with Horizon Pharma plc as the name of the resulting company, and will be organized under the laws of Ireland with a portfolio of four products marketed primarily in the United States. Horizon Pharma also stated that Vidara will combine with the Company, with approximately 74% of Horizon Pharma plc's ordinary shares to be exchanged for Horizon Pharma's common shares, with Horizon surviving the merger. The shareholders of Vidara will retain approximately 26% of Horizon Pharma plc and receive $200 million in cash, subject to certain adjustments. Pending execution of its final financing plans, the Company has secured a $250 million bridge loan commitment from Deerfield Management Company, L.P. The full analyst notes on Horizon Pharma Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03262014/HZNP/report.pdf
AlkermesPlcAnalystNotes
On March 6, 2014, Alkermes Plc (Alkermes) launched FORWARD (Focused On Results With A Rethinking of Depression), a comprehensive pivotal program for ALKS 5461 - a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). According to the Company, FORWARD includes a total of 12 studies, including three core phase 3 efficacy studies and nine supportive studies. The first FORWARD study, evaluating the onset of clinical effect, safety and tolerability of ALKS 5461 in approximately 60 patients with MDD, has begun, and the three core efficacy studies are expected to begin in mid-2014. The primary efficacy endpoint for the three core efficacy studies will be the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) scores. The full analyst notes on Alkermes Plc are available to download free of charge at:
http://www.AnalystsReview.com/03262014/ALKS/report.pdf
AgilentTechnologiesInc.AnalystNotes
On March 19, 2014, Agilent Technologies Inc. (Agilent) has appointed George A. Scangos, Ph.D., CEO and Director of Biogen Idec to its Board of Directors, effective September 2014. He replaces Dr. David Lawrence, who is retiring from the Agilent board after 13 years of service. James G. Cullen, Agilent Chairman stated, "I am delighted to welcome Dr. Scangos to the board. He has an extraordinary combination of biotechnology and business expertise along with insights that come from running a large successful global pharma company." Scangos is currently an adjunct professor of Biology at John Hopkins University. He has served as President and CEO of Exelixis Inc., and was previously President of Bayer Biotechnology. The full analyst notes on Agilent Technologies Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03262014/A/report.pdf
Becton,DickinsonandCo.AnalystNotes
On March 19, 2014, Becton, Dickinson and Co. (BD) announced that BD Diagnostics has received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for nasopharyngeal swab specimens on the BD Veritor' System for Rapid Detection of Respiratory Syncytial Virus (RSV). According to the Company, it is the first commercially available rapid CLIA-waived RSV test system that incorporates a digital result. The new assay is cleared for use in physician offices, hospitals, and other patient-care settings. It was also stated that when used in conjunction with the BD Veritor System Reader, the RSV test utilizes Advanced Nano-particle and Adaptive Read technologies to obtain an accurate result while providing objective results on a hand held reader with an easy-to-read digital display. The full analyst notes on Becton, Dickinson and Co. are available to download free of charge at:
http://www.AnalystsReview.com/03262014/BDX/report.pdf
AboutAnalystsReview
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
=============
EDITORNOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- Foranyurgentconcernsorinquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCEPROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOTFINANCIALADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NOWARRANTYORLIABILITYASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AnalystsReview.com
SOURCE Analysts Review
